Exposure to trimethoprim/sulfamethoxazole but not other FDA category C and D anti-infectives is associated with increased risks of preterm birth and low birth weight

International Journal of Infectious Diseases

Volumn 15, Issue 5, 2011, Pages

  Yang, Jianzhou ^a,b,c   Xie, Ri Hua ^c,d,e   Krewski, Daniel ^b   Wang, Yong Jin ^a   Walker, Mark ^c,d   Wen, Shi Wu ^c,d  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e HUAIHUA MEDICAL COLLEGE   (China)

Author keywords

Anti infectives; Folic acid antagonist; Low birth weight; Pregnancy; Preterm birth; Trimethoprim sulfamethoxazole

Indexed keywords

CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; FLUCONAZOLE; TETRACYCLINE;

ADULT; ADVERSE OUTCOME; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; ENVIRONMENTAL EXPOSURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANCY OUTCOME; PREMATURE LABOR; RANDOM SAMPLE; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; ANTI-INFECTIVE AGENTS; CHRONIC DISEASE; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; RETROSPECTIVE STUDIES; RISK FACTORS; SASKATCHEWAN; SOCIOECONOMIC FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 79954632191     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.01.007     Document Type: Article

References (57)

1. Andrade S.E., Gurwitz J.H., Davis R.L., Chan K.A., Finkelstein J.A., Fortman K., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004, 191:398-407.
2. Czeizel A.E., Rockenbauer M., Olsen J. Use of antibiotics during pregnancy. Eur J Obstet Gynecol Reprod Biol 1998, 81:1-8.
3. US Food Drug Administration Requirements on content and format of labeling for human prescription drug and biological products. Fed Regist 2006, 71:3921-3997.
4. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk 2008, Williams & Wilkins, Baltimore. 8th ed.
5. Nicolle L., Anderson P.A., Conly J., Mainprize T.C., Meuser J., Nickel J.C., et al. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physician 2006, 52:612-618.
6. Fihn S.D. Clinical practice: acute uncomplicated urinary tract infection in women. N Engl J Med 2003, 349:259-266.
7. Wen S.W., Zhou J., Yang Q., Fraser W., Olatunbosun O., Walker M., et al. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. CMAJ 2008, 179:1263-1268.
8. Lambie D.G., Johnson R.H. Drugs and folate metabolism. Drugs 1985, 30:145-155.
9. Hernández-Díaz S., Werler M.M., Walker A.M., Mitchell A.A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000, 343:1608-1614.
10. Hernández-Díaz S., Werler M.M., Walker A.M., Mitchell A.A. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001, 153:961-968.
11. Wilson A.G., Micek S.T., Ritchie D.J. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin Ther 2005, 27:1228-1237.
12. Avci I.Y., Kilic S., Acikel C.H., Ucar M., Hasde M., Eyigun C.P., et al. Outpatient prescription of oral antibiotics in a training hospital in Turkey: trends in the last decade. J Infect 2006, 52:9-14.
13. Cunha B.A. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am 2006, 90:1089-1107.
14. Boedeker K.S., Kilzer W.J. Fluconazole dose recommendation in urinary tract infection. Ann Pharmacother 2001, 35:369-372.
15. Burkhard F.C., Blick N., Hochreiter W.W., Studer U.E. Urinary urgency and frequency, and chronic urethral and/or pelvic pain in females. Can doxycycline help?. J Urol 2004, 172:232-235.
16. Lopez-Rangel E., Van Allen M.I., Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005, 73:919-923.
17. Moutier R., Tchang F., Caucheteux S.M., Kanellopoulos-Langevin C. Placental anomalies and fetal loss in mice, after administration of doxycycline in food for tet-system activation. Transgenic Res 2003, 12:369-373.
18. Drinkard C.R., Shatin D., Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000, 9:549-556.
19. Rothman K.F., Pochi P.E. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988, 19:431-442.
20. Jick S.S. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999, 19:221-222.
21. Sørensen H.T., Nielsen G.L., Olesen C., Larsen H., Steffensen F.H., Schønheyder H.C., et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999, 48:234-238.
22. Kazy Z., Puhó E.H., Czeizel A.E. Effect of doxycycline treatment during pregnancy for birth outcomes. Reprod Toxicol 2007, 24:279-280.
23. Elder H.A., Santamarina B.A., Smith S., Kass E.H. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol 1971, 111:441-462.
24. Jepsen P., Skriver M.V., Floyd A., Lipworth L., Schønheyder H.C., Sørensen H.T. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 2003, 55:216-221.
25. Hauth J.C., Goldenberg R.L., Andrews W.W., DuBard M.B., Copper R.L. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995, 333:1732-1736.
26. Kazy Z., Puhó E.H., Czeizel A.E. The possible preterm birth preventive effect of ampicillin during pregnancy. Arch Gynecol Obstet 2006, 274:215-221.
27. Shennan A., Crawshaw S., Briley A., Hawken J., Seed P., Jones G., et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG 2006, 113:65-74.
28. Wen S.W., Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can 2004, 26:475-480.
29. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194:961-966.
30. Von Korff M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
31. Chen X.K., Wen S.W., Sun L.M., Yang Q., Walker M.C., Krewski D. Recent oral contraceptive use and adverse birth outcomes. Eur J Obstet Gynecol Reprod Biol 2009, 144:40-43.
32. Andrade S.E., Raebel M.A., Morse A.N., Davis R.L., Chan K.A., Finkelstein J.A., et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006, 15:546-554.
33. Nelson J.W., Werler M.M. Socioeconomic status as a modifier of the relationship between antibiotic use during pregnancy and birthweight. Birth 2008, 35:196-203.
34. Jaddoe V.W., Troe E.J., Hofman A., Mackenbach J.P., Moll H.A., Steegers E.A., et al. Active and passive maternal smoking during pregnancy and the risks of low birthweight and preterm birth: the Generation R Study. Paediatr Perinat Epidemiol 2008, 22:162-171.
35. Vardavas C.I., Chatzi L., Patelarou E., Plana E., Sarri K., Kafatos A., et al. Smoking and smoking cessation during early pregnancy and its effect on adverse pregnancy outcomes and fetal growth. Eur J Pediatr 2010, 169:741-748.
36. Dugandzic R., Dodds L., Stieb D., Smith-Doiron M. The association between low level exposures to ambient air pollution and term low birth weight: a retrospective cohort study. Environ Health 2006, 5:3-10.
37. Hansen C., Neller A., Williams G., Simpson R. Maternal exposure to low levels of ambient air pollution and preterm birth in Brisbane, Australia. BJOG 2006, 113:935-941.
38. Solimani F. Developmental outcome of low-birth-weight premature infants. Iran J Pediatr 2007, 17(S1):125-135.
39. Boyle Torrey B, Haub C. Diverging mortality and fertility trends: Canada and the United States. Population Reference Bureau, USA. Population Bulletin 2002;57:11. Available at: (accessed January 2011). http://www.prb.org/pdf/57.4_USPopulationFINAL.pdf.
40. Rahim A., Ram B. Emerging patterns of child-spacing in Canada. J. Biosoc. Sci. 1993, 25:155-167.
41. Bánhidy F., Ács N., Czeizel E.H., Puhó A.E. Pregnancy complications and birth outcomes of pregnant women with urinary tract infections and related drug treatments. Can J Infect Dis 2007, 39:390-397.
42. Friso S., Choi S.W. Gene-nutrient interactions and DNA methylation. J Nutr 2002, 132(8 Suppl):2382S-2387S.
43. Czeizel A.E. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ 1993, 306:1645-1648.
44. Shaw G.M., O'Malley C.D., Wasserman C.R., Tolarova M.M., Lammer E.J. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995, 59:536-545.
45. Bodnar L.M., Tang G., Ness R.B., Harger G., Roberts J.M. Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 2006, 164:470-477.
46. Hernandez-Diaz S., Werler M.M., Louik C., Mitchell A.A. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 2002, 156:806-812.
47. Wen S.W., Chen X.K., Rodger M., White R.R., Yang Q., Smith G.N., et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008, 198. 45.el-7.
48. Ray J.G., Laskin C. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999, 20:519-529.
49. Tamura T., Goldenberg R.L., Freeberg L.E., Cliver S.P., Cutter G.R., Hoffman H.J. Maternal serum folate and zinc concentrations and their relationships to pregnancy outcome. Am J Clin Nutr 1992, 56:365-370.
50. Baumslag N., Edelstein T., Metz J. Reduction of incidence of prematurity by folic acid supplementation in pregnancy. Br Med J 1970, 1:16-17.
51. Callaway L., Colditz P.B., Fisk N.M. Folic acid supplementation and spontaneous preterm birth: adding grist to the mill?. PLoS Med 2009, 6:e1000077.
52. Bukowski R., Malone F.D., Porter F.T., Nyberg D.A., Comstock C.H., Hankins G.D., et al. Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. PLoS Med 2009, 6:e1000061.
53. Lopez-Rangel E., Van Allen M.I. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A. Clin Mol Teratol 2005, 73:919-923.
54. Tiboni G.M., Iammarrone E., Giampietro F., Lamonaca D., Bellati U., Di Ilio C. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 1999, 59:81-87.
55. Witt A., Sommer E.M., Cichna M., Postlbauer K., Widhalm A., Gregor H., et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003, 188:816-819.
56. Czeizel A.E., Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997, 89:524-528.
57. Czeizel A.E., Puhó H.E., Langmar Z., Ács N., Bánhidy F. Possible association of folic acid supplementation during pregnancy with reduction of preterm birth: a population-based study. Eur J Obstet Gynecol Reprod Biol 2010, 148:135-140.